C.H. Nagri Eye Hospital And Eye Research Foundation Ellisbridge, Ahmedabad-380006
To evaluate the therapeutic effect of subconjunctival Bevacizumabon corneal neovascularisation
A prospective randomized noncomparative study.
The charts of 10 consecutive patients with corneal neovascularisation who received single S.C. inj. of Bevacizumab (2.5mg/0.1ml) were reviewed. Digital photographs of the cornea were taken pre & post injection & then at 1 wk,3wk & 2months duration. Digital photographs of the cornea were analyzed to determine the length, density, extent, centricity of corneal neovascularisation and the area of cornea covered by neovascularisation as a percentage of the total corneal area.
Subconjunctival injection of Bevacizumab (Avastin) caused significant regression of corneal neovascularisation in 1 pt, partial regression in 6 pts and no effect in 3 pts as measured by length and surface area of neovascularisation. No significant ocular or systemic complications were found.
Subconjunctival inj. of Bevacizumab is effective in regressing corneal neovascularisation.
corneal neovascularisation, Bevacizumab (Avastin), Immunologic rejection, vascular endothelial growth factor
